INN,Target.s.,Indications.of.clinical.studies,Record.category,Most.advanced.stage.of.development..global.
Racotumomab,NeuGcGM3 idiotype,"Neuroblastoma;   Ewing's Sarcoma;   Wilm's Tumor;   Retinoblastoma;   Glioma, Non-small Cell Lung Cancer",Approved,Approved
Pertuzumab,HER2,"Non-small cell lung cancer,  pancreatic, ovarian, breast, prostate, neuroendocrine cancer",Approved,Approved
Abciximab,GP IIb/IIIa receptor,Prevention of blood clots,Approved,Approved
Zimberelimab,PD-1,"Melanoma, Colorectal cancer, Metastatic Castrate Resistant Prostate Cancer, GI malignancies, Cervical cancer, non-small cell lung cancer, Hodgkin lymphoma, advanced malignancies",Approved,Approved
Risankizumab,IL-23p19,"Atopic dermatitis, Psoriasis, Crohn's Disease, asthma, Ankylosing spondylitis, psoriatic arthritis",Approved,Approved
Raxibacumab,B. anthracis (PA),Anthrax infection,Approved,Approved
Panitumumab,EGFR,"Renal, prostate, lung, breast, colorectal Cancers",Approved,Approved
Emicizumab,"Factor IXa, Factor X",Hemophilia A,Approved,Approved
Canakinumab,IL-1 beta,"COVID-19, Cryopyrin-Associated Periodic Syndromes, Rheumatoid arthritis, wet age-related macular degeneration, Atherosclerosis and Either T2DM or IGT, Type 2 Diabetes, gout, juvenile arthritis ",Approved,Approved
Loncastuximab tesirine,CD19,"Non-Hodgkin lymphoma, B-ALL",Approved,Approved
Secukinumab,IL-17A,"Atopic dermatitis, Rheumatoid Arthritis, Plaque-type Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Multiple Sclerosis, Crohn's Disease, Uveitis, Asthma",Approved,Approved
Cadonilimab,"PD-1, CTLA-4","Pancreatic cancer, Clear Cell Renal Cell Carcinoma, Non-small cell lung cancer, MSI-H/dMMR Solid Tumor, Cervical cancer, Hepatocellular carcinoma, peripheral T-cell lymphoma, Melanoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Solid tumors",Approved,Approved
Penpulimab,PD-1,"Hodgkin's disease, Hepatocellular carcinoma, MSI-H or dMMR Advanced Solid Tumors, Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors (single Phase 2 study); Hepatocellular Carcinoma, Non-small cell lung cancer, Nasopharyngeal Carcinoma, solid tumors",Approved,Approved
Eptinezumab,CGRP,Migraine prevention,Approved,Approved
Caplacizumab,von Willebrand factor,"Acquired Thrombotic Thrombocytopenic Purpura, Unstable Angina;   Non-ST Segment Elevation Myocardial Infarction (NSTEMI);   Stable Angina (Associated With High Risk PCI), Thrombotic Thrombocytopenic Purpura",Approved,Approved
Ravulizumab,Complement C5,"Neuromyelitis Optica Spectrum Disorder, Generalized myasthenia gravis, Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome",Approved,Approved
Evolocumab,PCSK9,"Hypercholesterolemia and High Risk for Cardiovascular Events, homozygous familial hypercholesterolemia",Approved,Approved
Denosumab,RANK-L,"Osteoporosis, Breast Cancer With Bone Metastasis",Approved,Approved
Erenumab,CGRP receptor,"Migraine, Vasomotor Symptoms; Hot Flashes",Approved,Approved
Romosozumab,Sclerostin,"Postmenopausal Osteoporosis, Fracture Healing",Approved,Approved
Brodalumab,IL-17RA,"Systemic Sclerosis, Palmoplantar Pustulosis, Rheumatoid Arthritis, Psoriatic Arthritis, Asthma, Psoriasis, Crohn's Disease",Approved,Approved
Tezepelumab,TSLP,"Chronic Rhinosinusitis With Nasal Polyps, COPD, asthma, cat allergy, Atopic Dermatitis",Approved,Approved
Natalizumab,Integrin alpha-4,"Multiple sclerosis, Crohn's disease, ulcerative colitis",Approved,Approved
Dinutuximab,GD2,Neuroblastoma,Approved,Approved
Enfortumab vedotin,Nectin-4,Metastatic Urothelial Cancer and Other Malignant Solid Tumors,Approved,Approved
Eculizumab,Complement C5,"Membranous Nephritis, Rheumatoid Arthritis, Lupus, Psoriasis, Dermatomyositis",Approved,Approved
"Cilgavimab, Tixagevimab",SARS-CoV-2 (spike protein),COVID-19,Approved,Approved
Lecanemab,Amyloid beta (protofibrils),Alzheimer's Disease,Approved,Approved
Netakimab,IL-17A,"Ankylosing Spondylitis, Psoriasis, psoriatic arthritis",Approved,Approved
Levilimab,IL-6R,"COVID-19, rheumatoid arthritis, Phase 1 in healthy volunteers",Approved,Approved
Prolgolimab,PD-1,"Non-small cell lung cancer, Melanoma, Solid tumors",Approved,Approved
Divozilimab,CD20,"Neuromyelitis Optica Spectrum Disorders, Systemic Scleroderma, Multiple sclerosis",Approved,Approved
Tislelizumab,PD-1,"Bladder cancer, esophageal Squamous Cell Carcinoma, Hepatocellular Carcinoma, Non-small cell lung cancer, Hodgkin lymphoma, liver cancer, Advanced Cancer",Approved,Approved
Idarucizumab,Dabigatran,Hemorrhage caused by anticoagulation effect of dabigatran,Approved,Approved
Spesolimab,IL-36R,"Hidradenitis Suppurativa, Crohn's disease, palmoplantar pustulosis, Generalized pustular psoriasis, ulcerative colitis, atopic dermatitis",Approved,Approved
Aducanumab,Amyloid beta,Alzheimer's Disease,Approved,Approved
Sutimlimab,Complement C1s,"Idiopathic Thrombocytopenic Purpura, Chronic immune thrombocytopenia, Complement-mediated disorders",Approved,Approved
Elotuzumab,SLAMF7,Multiple Myeloma,Approved,Approved
Relatlimab,LAG-3,"Multiple myeloma, melanoma, gastric cancer, colorectal cancer, glioblastoma, non-small cell lung cancer, solid tumors,  Chronic lymphocytic leukemia and lymphomas",Approved,Approved
Mosunetuzumab,"CD20, CD3","
Systemic Lupus Erythematosus, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Non-Hodgkin's Lymphoma, NHL and Chronic Lymphocytic Leukemia (first Phase 1)",Approved,Approved
Alemtuzumab,CD52,"Multiple sclerosis, chronic lymphocytic leukemia",Approved,Approved
Tralokinumab,IL-13,"Atopic dermatitis, Asthma, Idiopathic Pulmonary Fibrosis, Ulcerative Colitis",Approved,Approved
Olokizumab,IL-6,"COVID-19, Crohn's Disease, Rheumatoid Arthritis",Approved,Approved
Certolizumab pegol,TNF,"Rheumatoid arthritis, Crohn's disease ",Approved,Approved
Infliximab,TNF,"Rheumatoid arthritis, Crohn's disease, ulcerative colitis",Approved,Approved
Reslizumab,IL-5,"Eosinophilic Asthma, Eosinophilic Esophagitis",Approved,Approved
Basiliximab,CD25,Transplant rejection,Approved,Approved
Nemolizumab ,IL-31R alpha,"Systemic sclerosis, Chronic Kidney Disease Associated Severe Pruritus, Prurigo Nodularis, Atopic dermatitis, pruritus in dialysis patients",Approved,Approved
Gemtuzumab ozogamicin,CD33, Acute myeloid leukemia ,Approved,Approved
Inotuzumab ozogamicin,CD22,"non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma",Approved,Approved
Guselkumab,IL-23p19,"Lupus Nephritis, Palmoplantar Pustulosis, Psoriasis, Rheumatoid arthritis",Approved,Approved
Ustekinumab,IL-12/23 p40,"Atopic dermatitis, Psoriasis, Crohn's disease, multiple sclerosis, sarcoidosis, psoriatic arthritis",Approved,Approved
Golimumab,TNF,"Rheumatoid arthritis, asthma, ulcerative colitis, ankylosing spondylitis, Sarcoidosis",Approved,Approved
Siltuximab,IL-6,"COVID-19, Multiple Myeloma, Multicentric Castleman's Disease, Ovarian Neoplasms;   Pancreatic Neoplasms;   Colorectal Neoplasms;   Head and Neck Neoplasms;   Lung Neoplasms, Prostate cancer, Renal cell carcinoma, Myelodysplastic Syndrome",Approved,Approved
Tremelimumab,CTLA-4,"Small cell lung cancer, Colorectal Neoplasms, Malignant Mesothelioma, Prostate cancer, Bladder cancer, Melanoma, Hepatocellular Carcinoma ",Approved,Approved
Sugemalimab ,PD-L1,"Head and neck cancer, endometrial cancer, small cell lung cancer, gastric cancer, non-small cell lung cancer, solid tumors, lymphomas",Approved,Approved
Regdanvimab,SARS-CoV-2 (spike protein),COVID-19,Approved,Approved
Adalimumab,TNF,Rheumatoid arthritis,Approved,Approved
"Trastuzumab deruxtecan, [fam]-Trastuzumab deruxtecan ",HER2,"Colorectal cancer, gastric cancer, HER2+ breast cancer, Urothelial Carcinoma, Advanced solid tumors",Approved,Approved
Itolizumab,CD6,"Graft v host disease, Lupus nephritis, Plaque psoriasis, rheumatoid arthritis",Approved,Approved
Obiltoxaximab,B. anthracis (PA),Inhalational anthrax,Approved,Approved
Epcoritamab,"CD20, CD3","Diffuse Large B-Cell Lymphoma, Follicular lymphoma, Non-Hodgkin's lymphoma, chronic Lymphocytic Leukemia, Hematologic cancers",Approved,Approved
Serplulimab,PD-1,"Colorectal cancer, Hepatocellular Carcinoma, Triple Negative Breast Cancer, Hepatitis B, Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Cancer",Approved,Approved
Zuberitamab,CD20,"Primary immune thrombocytopenia, B cell lymphoma",Approved,Approved
Naxitamab,GD2,Neuroblastoma; osteosarcoma,Approved,Approved
Ofatumumab,CD20,"Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinaemia, rheumatoid arthritis, large-cell diffuse lymphoma, follicular lymphoma, multiple sclerosis",Approved,Approved
Daratumumab,CD38,Multiple Myeloma,Approved,Approved
Tisotumab vedotin,Tissue factor,"Cervical cancer, Solid tumors",Approved,Approved
Nimotuzumab,EGFR,"Head and neck cancer, nasopharyngeal cancer, glioma, Esophageal cancer, pancreatic cancer, non-small cell lung cancer",Approved,Approved
Pucotenlimab,PD-1,"Non-small Cell Lung Cancer, melanoma, Hepatocellular Carcinoma, Bladder Cancer, Melanoma, Anaplastic Thyroid Cancer, gastric cancer, solid tumors",Approved,Approved
Tafolecimab,PCSK9,Hypercholesterolemia,Approved,Approved
Sintilimab,PD-1,"Liver cancer, gastric cancer, solid tumors, non-small cell lung cancer, Esophageal cancer, Hodgkin's lymphoma",Approved,Approved
Rituximab,CD20,Non-Hodgkin's  B-cell lymphoma,Approved,Approved
Ibritumomab tiuxetan,CD20,Non-Hodgkin's  B-cell lymphoma,Approved,Approved
Ramucirumab,VEGFR2,"Gastric Cancer;   Adenocarcinoma, Hepatocellular Carcinoma, breast cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, melanoma, Stomach Cancer;   Esophageal Cancer, Carcinoma of Urinary Tract;   Urethral Carcinoma; Carcinoma of Ureter;  Carcinoma of Renal Pelvis",Approved,Approved
Necitumumab,EGFR,"Non Small Cell Lung Cancer, Metastatic Colorectal Cancer, Solid Tumors",Approved,Approved
Cetuximab,EGFR,"Head and neck cancer, colorectal, non-small cell lung cancer",Approved,Approved
Tebentafusp,"CD3, gp100","Uveal melanoma, malignant melanoma",Approved,Approved
Mirvetuximab soravtansine,FR alpha,"Epithelial malignancies e.g., ovarian cancer adenocarcinoma",Approved,Approved
Sacituzumab govitecan,TROP-2,"Triple negative breast cancer, metastatic urothelial cancer, Advanced Epithelial Cancers",Approved,Approved
Retifanlimab,PD-1,"Head & neck cancer, Urothelial Carcinoma, Squamous Cell Carcinoma of the Anal Canal, Triple negative breast cancer, Liposarcoma, Penile Cancer, Glioblastoma, Non-small cell lung cancer, Pancreatic Cancer, Merkel cell carcinoma, squamous cell carcinoma, Colorectal cancer, advanced solid tumors",Approved,Approved
Camrelizumab,PD-1,"Esophageal Carcinoma, Hepatocellular Carcinoma, non-small cell lung cancer, melanoma, Advanced solid tumors, Nasopharyngeal Carcinoma, Hodgkin lymphoma, breast cancer, incl. triple-negative",Approved,Approved
Narlumosbart,RANK-L,"Giant Cell Tumor of Bone, Refractory Hypercalcemia of Malignancy, Bone metastases, osteoporosis",Approved,Approved
Amivantamab,"EGFR, cMET","Colorectal cancer, non-small cell lung cancer, gastric or esophageal cancer",Approved,Approved
Teclistamab,"BCMA, CD3",Multiple myeloma,Approved,Approved
Talquetamab,"GPRC5D, CD3",Multiple myeloma,Approved,Approved
Pabinafusp alfa,TfR,Hunter syndrome (mucopolysaccharidosis II),Approved,Approved
Toripalimab ,PD-1,"Non-small cell lung cancer; advanced solid tumors, breast cancer, melanoma, bladder cancer, neuroendocrine, Phase 1/2 study including Gastric Adenocarcinoma;   Esophageal Squamous Cell Carcinoma;  Nasopharyngeal Carcinoma;   Head and Neck Squamous Cell Carcinoma",Approved,Approved
Benralizumab,IL-5R alpha,"Atopic dermatitis, Eosinophilic Esophagitis, Asthma, Chronic Obstructive Pulmonary Disease",Approved,Approved
Envafolimab,PD-L1,"HIV infection, Metastatic or recurrent non-microsatellite highly unstable (non-MSI-H)/non-DNA mismatch repair defect (non-dMMR) endometrial cancer, Undifferentiated Pleomorphic Sarcoma, Hepatitis B, Bile tract carcinoma, solid tumors",Approved,Approved
Burosumab,FGF23,X-linked Hypophosphatemia,Approved,Approved
Mogamulizumab,CCR4,"Adult T-Cell leukemia and lymphoma, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphoma, Cutaneous T-Cell Lymphoma",Approved,Approved
Ixekizumab,IL-17A,"Psoriatic arthritis, Rheumatoid Arthritis, Psoriasis",Approved,Approved
Galcanezumab,CGRP,Migraine,Approved,Approved
Mirikizumab,IL-23p19,"Ulcerative colitis, psoriasis, Crohn's disease",Approved,Approved
Ansuvimab,Ebola virus glycoprotein,Ebola infection,Approved,Approved
Ipilimumab,CTLA-4,"Melanoma; lung, liver, brain, prostate, pancreatic, head & neck cancers",Approved,Approved
Nivolumab,PD-1,"Renal Cell Carcinoma, Malignant Melanoma, Non-small Cell Lung Cancer, Prostrate Cancer, hematologic malignancy, Hepatitis C ",Approved,Approved
Bezlotoxumab,C. difficile (enterotoxin B),Clostridium Difficile Infection,Approved,Approved
Palivizumab,RSV (F glycoprotein),Prevention of RSV infection In high risk infants,Approved,Approved
Durvalumab,PD-L1,"Bladder cancer, Head & neck cancer, Non-small cell lung cancer; Solid tumors (advanced malignant melanoma, renal cell carcinoma, non-small cell lung cancer, or colorectal cancer)",Approved,Approved
Anifrolumab,IFNAR1,"Systemic Lupus Erythematosus, Scleroderma",Approved,Approved
Nirsevimab,RSV,Respiratory syncytial virus,Approved,Approved
Margetuximab,HER2,"HER2 Positive Cancers (breast, gastric)",Approved,Approved
Pembrolizumab,PD-1,"Solid Tumors, Melanoma, colorectal cancer, non-small cell lung cancer, hematological cancers, renal cancer",Approved,Approved
Vedolizumab,Integrin alpha-4 beta-7,"Colitis, Crohn's Disease",Approved,Approved
Tocilizumab,IL-6R,"COVID-19, Giant lymph node hyperplasia (Castleman's Disease), rheumatoid arthritis, multiple myeloma",Approved,Approved
Avelumab,PD-L1,"Gastric cancer, ovarian cancer, non-small cell lung cancer, Merckel cell carcinoma, Solid tumors, renal cell cancer",Approved,Approved
Inebilizumab,CD19,"IgG4 Related Disease, Myasthenia Gravis, Neuromyelitis Optica, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Scleroderma, Multiple Sclerosis",Approved,Approved
Blinatumomab,"CD19, CD3","B-precursor Acute Lymphoblastic Leukemia, non-Hodgkin lymphoma",Approved,Approved
Emapalumab,IFN gamma,Primary Hemophagocytic Lymphohistiocytosis; Phase 1 in heathy volunteers,Approved,Approved
Ormutivimab,Rabies virus (glycoprotein),Rabies (post-exposure),Approved,Approved
Concizumab,Tissue factor pathway inhibitor,"Haemophilia A and B With and Without Inhibitors, Hemophilia A",Approved,Approved
Elranatamab,"BCMA, CD3",Multiple myeloma,Approved,Approved
Teplizumab,CD3,"Type 1 Diabetes Mellitus, Diabetes",Approved,Approved
"Docaravimab, Miromavimab",Rabies virus (glycoprotein),Rabies (post-exposure),Approved,Approved
Disitamab vedotin,HER2,"Melanoma, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Urothelial Carcinoma, HER2-overexpressing solid tumors (gastric, urothelial), breast cancer",Approved,Approved
"Casirivimab, imdevimab",SARS-CoV-2 (spike protein),COVID-19,Approved,Approved
Evinacumab,ANGPTL3,"Homozygous Familial Hypercholesterolemia, Hypertriglyceridemia, Hypercholesterolemia",Approved,Approved
Cemiplimab,PD-1,"Cervical cancer, Head and neck cancers, Non-small cell lung cancer, Plasma cell myeloma, Basal cell carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Lymphoma, solid tumors, melanoma, renal cancer",Approved,Approved
Pozelimab,Complement C5,"Generalized Myasthenia Gravis, CD55-deficient Protein-losing Enteropathy, Paroxysmal nocturnal hemoglobinuria, Phase 1 in health volunteers, intended for ocular inflammatory and retinal degenerative diseases",Approved,Approved
Dupilumab,IL-4R alpha,"Nasal Polyps, atopic dermatitis, Asthma",Approved,Approved
Alirocumab,PCSK9,High cholesterol,Approved,Approved
Sarilumab,IL-6R,"COVID-19, Rheumatoid Arthritis, Ankylosing Spondylitis,",Approved,Approved
"Atoltivimab, odesivimab, Maftivimab",Ebola virus glycoprotein,Ebola infection,Approved,Approved
Ocrelizumab,CD20,"Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Lupus Nephritis",Approved,Approved
Lebrikizumab,IL-13,"Atopic dermatitis, Idiopathic pulmonary fibrosis, Asthma, Hodgkin's Lymphoma",Approved,Approved
Atezolizumab,PD-L1,"Bladder cancer, Renal cell carcinoma, Non-small cell lung cancer, Melanoma, Solid tumors, multiple myeloma",Approved,Approved
Polatuzumab vedotin,CD79b,"Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma or Diffuse Large B-Cell Lymphoma ",Approved,Approved
Ranibizumab,VEGF,Neovascular age-related macular degeneration,Approved,Approved
Omalizumab,IgE,"Asthma, allergic rhinitis",Approved,Approved
Bevacizumab,VEGF,"Renal Cell Carcinoma, colorectal, breast cancer",Approved,Approved
Cetuximab saratolacan,EGFR,Head and neck squamous cell carcinomas,Approved,Approved
Obinutuzumab,CD20,"Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma",Approved,Approved
Faricimab,"Ang-2, VEGF","Wet age-related macular degeneration, Choroidal Neovascularization, Diabetic Macular Edema",Approved,Approved
Glofitamab,"CD20, CD3e","Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Non-Hodgkin's lymphoma",Approved,Approved
Brolucizumab,VEGF,"Diabetic macular edema, Neovascular Age-related Macular Degeneration",Approved,Approved
Teprotumumab,IGF-1R,"Diffuse Cutaneous Systemic Sclerosis, Graves' Ophthalmopathy, Diabetic macular edema, Active thyroid eye disease (terminated for cancer indications Solid tumors, sarcoma, breast cancer, non-small cell lung cancer)",Approved,Approved
Satralizumab,IL-6R,"Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD), Rheumatoid arthritis",Approved,Approved
Isatuximab,CD38,"Plasma cell myeloma, multiple myeloma, T-cell Type Acute Leukemia-Precursor T-lymphoblastic Lymphoma/Leukaemia, Hematological cancers",Approved,Approved
Mepolizumab,IL-5,"Atopic dermatitis, Chronic obstructive pulmonary disease, Hypereosinophilic Syndrome, Asthma, Eosinophilic Oesophagitis, Eosinophilic Granulomatosis with Polyangiitis (aka Churg Strauss Syndrome), Nasal Polyps",Approved,Approved
Tildrakizumab,IL-23p19,"Psoriasis,  Ankylosing spondylitis and Non-Radiographic Axial Spondyloarthritis, Psoriatic Arthritis ",Approved,Approved
Ripertamab,CD20,Non-Hodgkin's lymphoma,Approved,Approved
Crizanlizumab,P-selectin,"COVID-19, Phase 1 in healthy subjects, vasoocclusion in sickle cell disease",Approved,Approved
Brentuximab vedotin,CD30,"Hodgkin's lymphoma, anaplastic large cell lymphoma, germ cell tumors, mesothelioma, lymphatic diseases, systemic lupus erythematosus",Approved,Approved
Lanadelumab,Plasma kallikrein,"COVID-19, Hereditary angioedema attacks",Approved,Approved
Adebrelimab,PD-L1,"Gastric cancer, Breast cancer, Non-small cell lung cancer, Small cell lung cancer, Solid tumors",Approved,Approved
Crovalimab,Complement C5,"Sickle cell disease, Atypical Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria",Approved,Approved
Fremanezumab,CGRP,Migraine (episodic and chronic),Approved,Approved
Ublituximab,CD20,"Multiple sclerosis, non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, neuromyelitis optica and neuromyelitis optica spectrum disorder",Approved,Approved
Ibalizumab,CD4,HIV Infections,Approved,Approved
"Trastuzumab emtansine, ado-trastuzumab emtansine",HER2,"Breast cancer, gastric cancer",Approved,Approved
Ozoralizumab,"TNF, Albumin",Rheumatoid Arthritis,Approved,Approved
Dostarlimab,PD-1,"Breast cancer, Ovarian cancer, Rectal Adenocarcinoma, solid tumors, endometrial cancer",Approved,Approved
Bimekizumab,"IL-17A, IL-17F","Hidradenitis Suppurativa, Psoriasis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis",Approved,Approved
Rozanolixizumab,FcRn,"Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis, Generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Primary immune thrombocytopenia, Myasthenia gravis ",Approved,Approved
Sotrovimab,SARS-CoV-2 (spike protein),COVID-19,Approved,Approved
Tafasitamab,CD19,"Mantle cell lymphoma, Diffuse Large B-cell Lymphoma, CLL, ALL, NHL",Approved,Approved
Socazolimab,PD-L1,"Biliary Tract Cancer, Urothelial Carcinoma, Esophageal Squamous Cell Carcinoma, Osteosarcoma, Small Cell Lung Cancer, Solid tumors, cervical cancer",Approved,Approved
Belimumab,BAFF,"Systemic Lupus Erythematosus, rheumatoid arthritis, Sjögren's Syndrome, Symptomatic Waldenstroms Macroglobulinaemia, Normalization of Alloantibody Levels in Sensitized Patients Awaiting Kidney Transplantation",Approved,Approved
Trastuzumab,HER2,"Breast, ovarian Cancer",Approved,Approved
Trinbelimab,Rhesus D,Hemolytic disease of newborn,Approved,Approved
Bavituximab,Phosphatidylserine,"Liver Cancer, Pancreatic Cancer, breast cancer, solid tumors, Non-small-cell Lung Cancer, hepatitis C, ",Terminated,Phase 3
Bulumtatug fuvedotin,Nectin-4,"Cervical Cancer, Triple-Negative Breast Cancer, Urothelial Carcinoma, Solid tumors",Clinical,Phase 3
Domvanalimab,TIGIT,"Head and neck carcinoma, Gastrointestinal Tract Malignancies, Melanoma, Non-small Cell Lung Cancer, Advanced malignancies",Clinical,Phase 3
Livmoniplimab,GARP/TGF beta complex,"NSCLC, Hepatocellular Carcinoma, Solid tumors",Clinical,Phase 2/3
Budigalimab,PD-1,"NSCLC, Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Head and neck cancer, Solid tumors, ovarian cancer, colorectal cancer, HIV",Clinical,Phase 2/3
Etentamig,"BCMA, CD3",Multiple myeloma,Clinical,Phase 3
Telisotuzumab vedotin,cMET,"Non-small cell lung cancer, advanced solid tumors",Regulatory review,Regulatory review
Telisotuzumab adizutecan,cMET,"Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma, Colorectal cancer, Solid tumors, Non-small cell lung cancer",Clinical,Phase 3
Lemzoparlimab ,CD47,"Myelodysplastic syndrome, Acute Myeloid Leukemia, Solid tumors or lymphomas",Clinical,Phase 3
Ulviprubart,KLRG1,"Inclusion Body Myositis, T-cell Large Granular Lymphocytic Leukemia",Clinical,Phase 2/3
Lutikizumab,"IL-1 alpha, IL-1 beta","Psoriatic Arthritis, Ulcerative colitis, Hidradenitis Suppurativa, Osteoarthritis",Clinical,Phase 3
Glenzocimab,GP VI,"Heart attack, Acute Ischemic Stroke, COVID-19, thrombotic diseases",Clinical,Phase 2/3
Botensilimab,CTLA-4,"Pancreatic cancer, Colorectal cancer, Melanoma, Advanced cancer",Clinical,Phase 2
Balstilimab,PD-1,"Angiosarcoma, Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer",Clinical,Phase 2
Pulocimab,VEGFR2,"Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, Solid tumors",Clinical,Phase 3
Gumokimab,IL-17A,"Psoriasis, ankylosing spondylitis",Regulatory review,Regulatory review
Ligufalimab,CD47,"Head & neck cancer, Higher-risk myelodysplastic syndrome, Gastric or Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Triple-negative Breast Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Solid Tumors or Lymphomas",Clinical,Phase 3
Manfidokimab,IL-4R alpha,"Asthma, Atopic Dermatitis, Phase 1 in healthy subjects",Clinical,Phase 3
Gefurulimab,"Complement C5, Albumin","Generalized Myasthenia Gravis, Proteinuria, Phase 1 in healthy volunteers",Clinical,Phase 3
Maridebart cafraglutide,"GIPR, GLP-1R","Type 2 Diabetes Mellitus, Obesity",Clinical,Phase 3
Xaluritamig,"STEAP1, CD3",Prostate cancer,Clinical,Phase 3
Imsidolimab,IL-36R,"Ichthyosis, EGFRi/MEKi-associated acneiform rash, Generalized pustular psoriasis, Phase 1 in healthy volunteers",Clinical,Phase 3
Potravitug,BK virus,BK virus infection,Clinical,Phase 2/3
Delpacibart etedesiran,TfR,Myotonic dystrophy,Clinical,Phase 3
Suvemcitug,VEGF,"Ovarian Cancer, macular degeneration",Regulatory review,Regulatory review
Tosatoxumab,S. aureus alpha toxin,"Secondary S. aureus bacterial pneumonia in COVID-19 patients, Pneumonia Due to Staphylococcus Aureus",Clinical,Phase 3
Suvratoxumab,S. aureus alpha toxin,Prevention of pneumonia caused by bacterial infection with Staphylococcus aureus in high-risk patients,No development reported,Phase 3
Empasiprubart,Complement C2,"Multifocal Motor Neuropathy, Dermatomyositis, Delayed Graft Function, Multifocal Motor Neuropathy, Phase 1 is in healthy volunteers",Clinical,Phase 3
Anvatabart opadotin,HER2,"HER2-positive, Metastatic Breast Cancer, Advanced Cancers With HER2 Expression",Clinical,Phase 3
Ficlatuzumab,HGF,"Pancreatic cancer, Head and neck cancer, Acute Myeloid Leukemia, Non-Small Cell-Lung cancer, Solid Tumor; Lymphomas; Multiple Myeloma",Clinical,Phase 3
Rilvegostomig,"PD-1, TIGIT","HER2+ gastric cancer, Biliary tract cancer, Non-small cell lung cancer",Clinical,Phase 3
Sipavibart,SARS-CoV-2 (spike protein),Pre Exposure Prophylaxis of COVID-19,Regulatory review,Regulatory review
Ficerafusp alfa,"EGFR, TGF beta","Head and Neck Squamous Cell Carcinoma, EGFR-Driven Advanced Solid Tumors",Clinical,Phase 2/3
Seniprutug,TCR Vbeta9,"Ankylosing Spondylitis, Axial Spondyloarthritis, Phase 1 in healthy volunteers",Approved,Approved
Nurulimab,CTLA-4,Melanoma,Approved,Approved
Ociperlimab,TIGIT,"Diffuse Large B-cell Lymphoma, Non-small cell lung cancer, Esophageal Squamous Cell Carcinoma, Solid tumors",Clinical,Phase 3
Litifilimab,BDCA2,"Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus ",Clinical,Phase 3
Izalontamab brengitecan,"EGFR, HER3","Chordoma, Glioblastoma, Small cell lung cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Triple-neg breast cancer, Non-small cell lung cancer (EGFR wild-type), Esophageal squamous cell carcinoma, Cervical cancer, Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer With EGFR-sensitive Mutations, Gynecological Malignant Tumor, Urinary tract cancer, Breast cancer, Gastrointestinal Tumors, Solid tumors",Clinical,Phase 3
Gotistobart,CTLA-4,"
Metastatic Castration-Resistant Prostate Cancer, Ovarian cancer, Solid tumors",Clinical,Phase 3
Bosakitug,TSLP,"Chronic Obstructive Pulmonary Disease, Asthma, Atopic dermatitis",Clinical,Phase 3
Anselamimab,Amyloid light chain,Amyloid light chain amyloidosis,Clinical,Phase 3
Rademikibart,IL-4R alpha,"Atopic dermatitis, asthma, Chronic Rhinosinusitis With Nasal Polyps",Clinical,Phase 3
Geptanolimab,PD-1,"Non-small cell lung cancer, Colorectal cancer, Hepatocellular and Renal Cell Carcinoma (Phase 1/2 study), Solid tumors",No development reported,Regulatory review
Cendakimab,IL-13,"Eosinophilic gastroenteritis, Atopic dermatitis, Asthma, Eosinophilic Esophagitis",Terminated,Terminated
Dapirolizumab pegol ,CD40L,Systemic Lupus Erythematosus,Clinical,Phase 3
Barzolvolimab,c-Kit,"Atopic dermatitis, Eosinophilic Esophagitis, Chronic Inducible Urticaria, Prurigo nodularis, Chronic Spontaneous Urticaria, Phase 1 in healthy volunteers (intended to treat CIU, a mast cell-related disease)",Clinical,Phase 3
Ziltivekimab,IL-6,"Atherosclerosis, Cardiovascular Risk and Heart Failure, Anemia, Chronic Kidney Diseases",Clinical,Phase 3
Nofazinlimab,PD-1,"Hepatocellular carcinoma, solid tumors",Clinical,Phase 3
Clazakizumab,IL-6,"Subjects With End Stage Kidney Disease Undergoing Dialysis, COVID-19, Acute GvHD, Psoriatic arthritis; Crohn's disease, Rheumatoid arthritis, Oral Mucositis, Non-Small Cell Lung Cancer-Related Fatigue and cachexia",Clinical,Phase 3
Trastuzumab pamirtecan,HER2,"Endometrial cancer, Breast cancer, Solid tumors",Clinical,Phase 3
Raludotatug deruxtecan,Cadherin-6,"Gastrointestinal Cancer, Non-small cell lung cancer, Ovarian cancer, Phase 1 in Renal Cell Carcinoma and Ovarian Tumors",Clinical,Phase 2/3
Ifinatamab deruxtecan,B7-H3,"Esophageal Squamous Cell Carcinoma, Small cell lung cancer, Solid tumors",Clinical,Phase 3
Etalanetug,Tau (MTBR),Alzheimer's disease,Clinical,Phase 2/3
Paridiprubart,TLR4,"Acute Respiratory Distress Syndrome, COVID-19, Rheumatoid arthritis",Clinical,Phase 2/3
Tovecimig,"DLL4, VEGF","Colorectal cancer, Solid tumors",Clinical,Phase 2/3
Rulonilimab,PD-1,"Non-small cell lung cancer, cervical carcinoma, Peripheral T Cell Lymphoma, Hepatocellular Carcinoma, Urothelial Cell Carcinoma",Clinical,Phase 2/3
Pamrevlumab,Connective tissue growth factor,"Pancreatic cancer, Duchenne muscular dystrophy, Idiopathic Pulmonary Fibrosis, Pancreatic Cancer, Liver Fibrosis Due to Chronic Hepatitis B Infection, Diabetes Mellitus;   Diabetic Nephropathy, focal segmental glomerulosclerosis",Terminated,Terminated
Bemarituzumab,FGFR2b,"Gastric and gastroesophageal junction adenocarcinoma, Solid tumors",Clinical,Phase 3
Zigakibart,APRIL,"IgA nephropathy, Multiple myeloma (terminated)",Clinical,Phase 3
Acasunlimab,"PD-L1, 4-1BB","Non-Small Cell Lung Cancer, Solid tumors",Clinical,Phase 3
Gulgafafusp alfa,GLP-1R,Diabetes,Clinical,Phase 3
Silevimig,Rabies virus (glycoprotein),Post exposure prophylaxis,Clinical,Phase 3
Telikibart,IL-4R alpha,"Allergic rhinitis, asthma, chronic urticaria, rhinosinusitis, atopic dermatitis",Clinical,Phase 3
Depemokimab,IL-5,"Hypereosinophilic Syndrome, Nasal Polyps, Eosinophilic Granulomatosis With Polyangiitis, Mild to Moderate Asthma",Regulatory review,Regulatory review
Cobolimab ,TIM3,"Non-small cell lung cancer, Solid tumors",Clinical,Phase 2/3
Belrestotug,TIGIT,"Multiple myeloma, non-small cell lung cancer, Solid tumors",Clinical,Phase 3
Latozinemab,Sortilin,"Amyotrophic lateral sclerosis, Frontotemporal Dementia",Clinical,Phase 3
Betinukibart,IL-17A,"Ankylosing spondylitis, Psoriasis, Phase 1 in healthy volunteers",Clinical,Phase 3
Apamistamab-Iodine (131I),CD45,Ablation of bone marrow prior to transplantation,Clinical,Phase 3
Picankibart,IL-23p19,"Ulcerative Colitis, Psoriasis",Regulatory review,Regulatory review
Teprotumumab N01,IGF-1R,"Thyroid associated ophthalmopathy, Phase 1 in healthy volunteers",Approved,Approved
Caxmotabart entudotin,HER2,Breast Cancer,Clinical,Phase 3
Brenetafusp,"PRAME, CD3",PRAME-Positive Cancers,Clinical,Phase 3
Pivekimab sunirine,CD123,"Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies (single Phase 1 study)",Clinical,Phase 2
Ozekibart,DR5,"Chondrosarcoma, Solid Tumors Including Sarcomas",Clinical,Phase 2
Becotatug,EGFR,"Non-Small Cell Lung Cancer, colon cancer",Clinical,Phase 3
Cetrelimab,PD-1,"Hepatitis B, Non-Muscle Invasive Bladder Cancer Unresponsive to Intravesical Bacillus Calmette-Guerin, Urothelial Carcinoma, prostate cancer, Multiple myeloma, Advanced cancer",Clinical,Phase 3
Nipocalimab,FcRn,"
Rheumatoid arthritis, Hemolytic Disease of the Fetus and Newborn, Myositis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Lupus Nephritis,  Lupus Erythematosus, Autoimmune Hemolytic Anemia, Generalized Myasthenia Gravis, Phase 1 in healthy volunteers",Regulatory review,Regulatory review
Tifcemalimab,BTLA,"Lung cancer, Head and Neck Squamous Cell Carcinoma/Nasopharyngeal Carcinoma, Recurrent/Refractory Malignant Lymphoma, Solid tumors",Clinical,Phase 3
Roconkibart,IL-17A,"Plaque Psoriasis, Psoriatic arthritis, spondylitis",Clinical,Phase 3
Anbenitamab repodatecan,"HER2, HER2","Ovarian cancer, Breast cancer, Solid tumors",Clinical,Phase 3
Lenzilumab,GM-CSF,"Chronic Myelomonocytic Leukaemia, COVID-19, CAR-T-related neurotoxicity, Leukemia, Rheumatoid Arthritis, Asthma",No development reported,Phase 2/3
Rocatinlimab,OX40,"Prurigo Nodularis, Asthma, Ulcerative colitis, atopic dermatitis",Clinical,Phase 3
Anbenitamab,"HER2, HER2",HER2+ breast and gastric cancers,Clinical,Phase 3
Erfonrilimab,"PD-L1, CTLA-4","Pancreatic Ductal Adenocarcinoma, Hepatocellular carcinoma, Gastro-intestinal tumors, thymic carcinoma, non-small cell lung cancer, colorectal cancer, triple-neg. breast cancer, solid tumors",Clinical,Phase 3
Tarcocimab tedromer,VEGF,"Diabetic Retinopathy, Diabetic Macular Edema, Wet Macular Degeneration",Clinical,Phase 3
"Bifikafusp alfa, Onfekafusp alfa",Fibronectin EDB,"Non-melanoma skin cancer, metastatic melanoma, Pancreatic Cancer, Solid Tumours",Regulatory review,Regulatory review
Onfekafusp alfa,"Fibronectin EDB, TNF","Glioblastoma, non-melanoma skin cancer, Glioma, soft tissue sarcoma, solid tumors; colorectal cancer; melanoma",Clinical,Phase 3
Amlenetug,Alpha synuclein,"Multiple System Atrophy, Parkinson's disease",Clinical,Phase 3
Remternetug,Amyloid beta (N3pG),Alzheimer disease,Clinical,Phase 3
Sonelokimab,"IL-17A, IL-17F, Albumin","Psoriatic arthritis, Hidradenitis suppurativa, psoriasis; Phase 1 in healthy volunteers",Clinical,Phase 3
Abelacimab,Factor XI,"Atrial Fibrillation, Thrombotic Disorders",Clinical,Phase 3
Zenocutuzumab,"HER2, HER3","Breast cancer, pancreatic cancer, solid tumors",Approved,Approved
Petosemtamab,"EGFR, LGR5","Head and neck cancer, Colorectal cancer",Clinical,Phase 3
Tozorakimab,IL-33,"Acute respiratory failure, Chronic Obstructive Pulmonary Disease/Chronic bronchitis. COVID-19, Atopic dermatitis, diabetic kidney disease, Phase 1 in Healthy Adult Subjects With a History of Mild Atopy and as Multiple Ascending Doses in Subjects COPD",Clinical,Phase 3
Volrustomig,"CTLA-4, PD-1","Colorectal cancer, Head and neck cancer, Pleural Mesothelioma, Hepatobiliary Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Non-small cell lung cancer, Advanced Renal Cell Carcinoma, Solid tumors",Clinical,Phase 3
Oleclumab,CD73,"Metastatic Non-Small Cell Lung Cancer, ovarian cancer, Solid tumors",Clinical,Phase 3
Comekibart,IL-4R alpha,"Prurigo nodularis, Atopic Dermatitis, Asthma",Clinical,Phase 3
Quavonlimab,CTLA-4,"Renal cell carcinoma, Melanoma, solid tumors",Clinical,Phase 3
Clesrovimab,RSV (F glycoprotein),RSV infection,Regulatory review,Regulatory review
Favezelimab,LAG-3,"Urothelial Carcinoma, Colorectal cancer, non-small cell lung cancer, renal cancer, B cell lymphoma, Solid tumors",Terminated,Phase 3
Vibostolimab,TIGIT,"Small Cell Lung Carcinoma, Non-small cell lung cancer, melanoma, Solid tumors",Terminated,Phase 3
Becotatug vedotin,EGFR,"Gastric cancer, Nasopharyngeal Carcinoma, Biliary Tract Cancer, Non-small cell lung cancer, Colorectal cancer, head and neck cancer",Regulatory review,Regulatory review
Tiragolumab,TIGIT,"Melanoma, Head and Neck cancer, Triple-Negative Breast Cancer, Esophageal Cancer, Liver cancer, Cervical Cancer, Small cell lung cancer, multiple myeloma/NHL (single Phase 1 study), non-small cell lung cancer, locally advanced or metastatic tumors",Clinical,Phase 3
Birtamimab,Amyloid light chain,Systemic amyloidosis,Clinical,Phase 3
Denecimig,"Factor IXa, Factor X",Hemophilia A,Clinical,Phase 3
Monalizumab,NKG2A,"Breast cancer, Non-small cell lung cancer, head & neck cancer (Phase 1/2), Chronic lymphocytic leukemia (Phase 1/2), Squamous Cell Carcinoma of the Oral Cavity (Phase 1/2), ovarian cancer, Rheumatoid Arthritis",Clinical,Phase 3
Magrolimab,CD47,"Triple-Negative Breast Cancer, Head & neck cancer, acute Myeloid Leukemia, Myeloid Malignancies, r/r DLBCL, ovarian cancer, colorectal cancer, non-Hodgkin's lymphoma, solid tumors, leukemia",Terminated,Phase 3
Bentracimab,Ticagrelor,Reversal of the antiplatelet effects of ticagrelor. ,Regulatory review,Regulatory review
Sasanlimab,PD-1,"Clear cell renal cell carcinoma, Non-small cell lung cancer, Non-muscle Invasive Bladder Cancer, melanoma, SCCHN, ovarian carcinoma, sarcoma, or relapsed or refractory cHL (one Phase 1 study), prostate cancer",Clinical,Phase 3
Dazukibart,IFN beta,"Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)], Lupus, Dermatomyositis",Clinical,Phase 3
Inclacumab,P-selectin,"Sickle Cell Disease, Peripheral Arterial Disease, Myocardial Infarction, Coronary Heart Disease, prevention of saphenous vein graft disease",Clinical,Phase 3
Tulisokibart,TL1a,"Systemic Sclerosis Associated With Interstitial Lung Disease, Crohn’s disease, Ulcerative colitis",Clinical,Phase 3
Rinatabart sesutecan,FR alpha,Solid tumors,Clinical,Phase 3
Ligelizumab,IgE,"Chronic Inducible Urticaria, Peanut allergy, Chronic Spontaneous Urticaria, Allergy, Asthma, Atopic Dermatitis, Bullous Pemphigoid",Terminated,Phase 3
Garetosmab,Activin A,Fibrodysplasia ossificans progressiva,Clinical,Phase 3
Itepekimab,IL-33,"Chronic Rhinosinusitis Without Nasal Polyps, Bronchiectasis, Chronic Obstructive Pulmonary Disease, Atopic dermatitis, Asthma, Phase 1 in healthy volunteers",Clinical,Phase 3
Fianlimab,LAG-3,"Non-small cell lung cancer, Melanoma, Advanced cancers",Clinical,Phase 3
Mibavademab,LEPR,"Obesity, Familial Partial Lipodystrophy, Generalized Lipodystrophy",Clinical,Phase 3
"Atisnolerbart, bremzalerbart, umesolerbart",Bet v 1,"Allergic Rhinitis Conjunctivitis, Allergy",Clinical,Phase 3
Emactuzumab,CSF-1R,"Tenosynovial Giant Cell Tumor, Malignant Neoplasms of Female Genital Organs, solid tumors",Clinical,Phase 3
Astegolimab,IL-33R,"Atopic Dermatitis, Chronic Obstructive Pulmonary Disease, COVID-19, Asthma, Chronic Rhinosinusitis With Nasal Polyps",Clinical,Phase 3
Vamikibart,IL-6,"Uveitic Macular Edema, Diabetic Macular Edema",Clinical,Phase 3
Afimkibart,TL1a,"Atopic Dermatitis, Crohn Disease, Ulcerative colitis",Clinical,Phase 3
Ersodetug,Insulin receptor,"Hypoglycemia after gastric bypass surgery, Congenital Hyperinsulinism, Hypoglycemia; Phase 1 in healthy volunteers",Clinical,Phase 3
Frexalimab,CD40L,"Diabetes, Systemic Lupus Erythematosus, Sjögren's Syndrome, Multiple sclerosis",Clinical,Phase 3
Riliprubart,Complement C1s,"Chronic Inflammatory Demyelinating Polyneuropathy, Transplant Rejection, autoimmune Haemolytic Anaemia, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Cold Agglutinin Disease",Clinical,Phase 3
Amlitelimab,OX40L,"Celiac Disease, Alopecia Areata, Hidradenitis, Asthma, Eczema, Atopic dermatitis",Clinical,Phase 3
Finotonlimab,PD-1,"Esophageal Squamous Cell Carcinoma, Colorectal Cancer, NSCLC, Head and neck cancer, Solid tumors",Approved,Approved
Sigvotatug vedotin,Integrin beta-6,"Non-small cell lung cancer, Solid tumors",Clinical,Phase 3
Retlirafusp alfa,"PD-L1, TGF beta","Rectal cancer, cervical Cancer, Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer, Small cell lung cancer, Pancreatic cancer, Non-small cell lung cancer, nasopharyngeal carcinoma, solid tumors",Regulatory review,Regulatory review
Drotokibart,IL-4R alpha,"Atopic Dermatitis, Asthma",Clinical,Phase 3
Trastuzumab rezetecan,HER2,"Gynecological malignancies, HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, Breast cancer, non-small cell lung cancer, gastric cancer or colorectal cancer, solid tumors",Regulatory review,Regulatory review
Tizetatug rezetecan,TROP-2,"Ovarian cancer, Solid tumors, B cell lymphoma",Clinical,Phase 3
Izalontamab,"EGFR, HER3","Head and Neck Squamous Cell Carcinoma, Non-small cell lung cancer, head and Neck Squamous Cell Carcinoma, Digestive System Malignancies (Colorectal and Gastric Cancer), Epithelium squamous cell carcinoma",Clinical,Phase 3
Apitegromab,Myostatin,"Preservation of lean muscle mass in individuals with obesity, Type 2 or Type 3 Spinal Muscular Atrophy, Phase 1 in health volunteers",Regulatory review,Regulatory review
Navenibart,Plasma kallikrein,Hereditary angioedema,Clinical,Phase 3
Luveltamab tazevibulin,FR alpha,"Acute Myeloid Leukemia, Lung cancer, Ovarian cancer",No development reported,Phase 2/3
"Mazorelvimab, Zamerovimab",Rabies virus (glycoprotein),Rabies (Phase 1 and 2 studies done in healthy adults),Approved,Approved
Ontamalimab,MADCAM-1,"Non-alcoholic steatohepatitis, Crohn's Disease, Ulcerative Colitis",Terminated,Terminated
Uliledlimab,CD73,"Non-small cell lung cancer, Ovarian cancer, Solid tumors",Clinical,Phase 2/3
Felzartamab,CD38,"Lupus nephritis, Immunoglobulin A (IgA) Nephropathy, Systemic lupus erythematosus, Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory), Multiple myeloma",Clinical,Phase 3
Rosopatamab tetraxetan 177Lu,PSMA,Prostate cancer,Clinical,Phase 3
Siltartoxatug,Tetanus toxin,Infection with  Clostridium bacteria,Approved,Approved
Setrusumab,Sclerostin,"Osteogenesis imperfecta, hypophosphatasia, low bone mineral density",Clinical,Phase 3
Ianalumab,BAFFR,"Diffuse Cutaneous Systemic Sclerosis, Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Systemic Lupus Erythematosus, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Autoimmune Hepatitis, Systemic Lupus Erythematosus, Pulmonary fibrosis, rheumatoid arthritis, Primary Sjögren's syndrome, Pemphigus Vulgaris, Relapse Remitting Multiple Sclerosis, Leukemia",Clinical,Phase 3
Tobevibart,HBV (HBsAg),"Chronic hepatitis delta, chronic hepatitis B infection",Clinical,Phase 3
Sibeprenlimab,APRIL,"IgA Nephropathy, Phase 1 in healthy subjects",Clinical,Phase 3
Zilovertamab vedotin,ROR1,"Diffuse Large B-Cell Lymphoma, Solid tumors, Hematological malignancies",Clinical,Phase 3
Veligrotug,IGF-1R,"Thyroid eye disease, breast cancer, liver cancer, multiple myeloma",Clinical,Phase 3
Obexelimab,CD19,"Warm Autoimmune Hemolytic Anemia, IgG4-related disease, Systemic Lupus Erythematosus, rheumatoid arthritis",Clinical,Phase 3
Trastuzumab botidotin,HER2,Solid tumors,Regulatory review,Regulatory review
Tagitanlimab,PD-L1,"Breast cancer, non-small cell lung cancer, nasopharyngeal cancer, Lymphoma, solid tumors",Approved,Approved
Ebdarokimab,IL-12/23 p40,"Plaque psoriasis, ulcerative colitis",Regulatory review,Regulatory review
Ebronucimab,PCSK9,"Hyperlipidemia, Homozygous Familial Hypercholesterolemia",Approved,Approved
Ivonescimab,"PD-1, VEGF","
Head and neck cancer, Cutaneous squamous cell carcinoma, Colorectal cancer, Hepatocellular Carcinoma, Small cell lung cancer, Triple-negative breast cancer, Ovarian cancer, Gynecological Tumors, Non-small cell lung cancer, Solid tumors",Approved,Approved
Tarlatamab,"DLL3, CD3","Small-cell lung cancer, neuroendocrine prostate cancer",Approved,Approved
Vilobelimab,Complement C5a,"Squamous Cell Carcinoma, COVID-19, Pyoderma Gangrenosum, ANCA-associated vasculitis, hidradenitis suppurativa, complex cardiac surgery, Sepsis",Approved,Approved
Benmelstobart,PD-L1,"Nasopharyngeal Carcinoma, Endometrial Cancer, Triple-neg breast cancer, Ovarian cancer, Small Cell Lung Cancer, Hodgkin's lymphoma, Head and Neck Squamous Cell Carcinoma, non-small cell lung cancer",Approved,Approved
Cosibelimab ,PD-L1,"Non-small cell lung cancer, cutaneous squamous cell carcinoma, advanced cancer, lymphoma",Approved,Approved
Stapokibart,IL-4R alpha,"Chronic Pruritus of Unknown Origin, Chronic Rhinosinusitis With Nasal Polyps, Severe asthma, COPD, atopic dermatitis",Approved,Approved
Garadacimab,Factor XIIa,"Idiopathic Pulmonary Fibrosis, Hereditary Angioedema, COVID-19, Phase 1 in healthy volunteers",Approved,Approved
Datopotamab deruxtecan,TROP-2,"Breast cancer, Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations, Solid tumors",Approved,Approved
Xeligekimab,IL-17A,"Psoriasis,  Axial Spondyloarthritis",Approved,Approved
Zolbetuximab,Claudin-18.2,"Pancreatic cancer, CLDN18.2-positive Gastric Adenocarcinoma;   CLDN18.2-positive Adenocarcinoma of Esophagus;   CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, solid tumors",Approved,Approved
Batoclimab,FcRn,"Chronic Inflammatory Demyelinating Polyneuropathy, generalized Myasthenia Gravis, Thyroid Eye Disease, Graves' ophthalmopathy, Adult immune thrombocytopenia, myasthenia Gravis, Neuromyelitis Optica Spectrum Disorders",Regulatory review,Regulatory review
Ongericimab,PCSK9,Hypercholesterolemia,Approved,Approved
Catumaxomab,"EPCAM, CD3","Malignant Ascites Due to Epithelial Carcinoma, ovarian cancer, gastric cancer",Approved,Approved
Donanemab,Amyloid beta (N3pG),Alzheimer disease,Approved,Approved
Narsoplimab,MASP-2,"Steroid-dependent IgA nephropathy, Thrombotic Microangiopathies, Atypical hemolytic uremic syndrome (Phase 1 in healthy volunteers)",Regulatory review,Regulatory review
Marstacimab,Tissue factor pathway inhibitor,"Severe hemophilia, Phase 1 in healthy subjects",Approved,Approved
"Iparomlimab, Tuvonralimab","PD-1, CTLA-4","Hepatocellular carcinoma, Nasopharyngeal Carcinoma, Non-small cell lung cancer, small cell lung cancer, renal cell carcinoma, cervical cancer, solid tumors",Approved,Approved
Iparomlimab,PD-1,Cervical Cancer,Regulatory review,Regulatory review
Odronextamab,"CD20, CD3","Follicular Lymphoma, DLBCL, CD20+ B-cell malignancies",Approved,Approved
Linvoseltamab,"BCMA, CD3","Chronic Kidney Disease, Multiple myeloma",Regulatory review,Regulatory review
Enlonstobart,PD-1,"Triple Negative Breast Cancer, Epithelial Ovarian Cancer, uterine cervical cancer, solid tumors",Approved,Approved
Recaticimab,PCSK9,"Hypercholesterolemia, Hyperlipidemia",Regulatory review,Regulatory review
Vunakizumab,IL-17A,"Graves' Orbitopathy, Lupus Nephritis, Ankylosing Spondylitis, Plaque Psoriasis, axial spondyloarthritis, Phase 1 in healthy volunteers",Approved,Approved
Sacituzumab tirumotecan,TROP-2,"Gastrointestinal cancers, Endometrial cancer, Triple-neg breast cancer, Non-small cell lung cancer, Solid tumors",Approved,Approved
Suciraslimab,CD22,"Systemic lupus erythematosus, rheumatoid arthritis, non-Hodgkin lymphoma ",Regulatory review,Regulatory review
Axatilimab ,CSF-1R,"Idiopathic Pulmonary Fibrosis,
Chronic Graft-versus-host-disease, COVID-19, solid tumors, Hodgkin's lymphoma, ",Approved,Approved
Patritumab deruxtecan,HER3,"Colorectal cancer, Breast cancer, non-small cell lung cancer",Regulatory review,Regulatory review
Zanidatamab,"HER2, HER2","Endometrial cancer, biliary tract cancer, breast cancer; HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas; ovarian cancer",Approved,Approved
Bapineuzumab,Amyloid beta (N-terminal),Alzheimer's disease,Terminated,Phase 3
Depatuxizumab mafodotin,EGFR,"Solid tumors, Glioblastoma Multiforme, squamous non-small cell lung cancer, pediatric brain tumors",Terminated,Phase 3
Briakinumab,IL-12/23 p40,"Crohn's disease, psoriasis, multiple sclerosis",Terminated,Regulatory review
Adintrevimab,SARS-CoV-2 (spike protein),COVID-19,Terminated,Phase 2/3
Lirentelimab,Siglec-8,"Atopic Dermatitis, eosinophilic Esophagitis, Eosinophilic Gastritis, Chronic Urticaria, Systemic mastocytosis, Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis",Terminated,Phase 3
Rilotumumab,HGF,"Glioma, Glioblastoma Multiforme,  Non-Small-Cell Lung cancer, Renal Cell Carcinoma, Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Small Cell Lung Cancer, Colorectal Cancer",Terminated,Phase 3
Brazikumab,IL-23p19,"Ulcerative colitis, psoriasis, Crohn's Disease",Terminated,Phase 3
Ganitumab,IGF-1R,"Pancreatic Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Askin's Tumors, Desmoplastic Small Round Cell Tumors, Extraosseous Ewing's Tumor, Ewing's Family Tumor, Ewing's Sarcoma; Breast Cancer",Terminated,Phase 3
Patritumab,HER3,"Solid tumors, Non-small Cell Lung Cancer, Breast Cancer, head and neck cancer",Terminated,Phase 3
Lomtegovimab,SARS-CoV-2 (spike protein),COVID-19,Terminated,Phase 2/3
Pagibaximab,Staphylococcal lipoteichoic acid,Staphylococcal Sepsis in very low birth weight neonates,Terminated,Phase 2/3
"Crexavibart, ogalvibart",SARS-CoV-2 (spike protein),COVID-19,Terminated,Phase 2/3
Sirukumab,IL-6,"COVID-19, Polymyalgia Rheumatica, Giant Cell Arteritis, Depressive disorder, Lupus Nephritis, Kidney Diseases, Kidney Insufficiency, Glomerulonephritis, Systemic Lupus Erythematosus, Rheumatoid arthritis, asthma",Terminated,Regulatory review
Figitumumab,IGF-1R,"Non-small cell lung cancer, multiple myeloma, breast cancer, prostate cancer, small cell lung cancer",Terminated,Phase 3
Coprelotamab,HER2,Breast cancer,Terminated,Phase 3
Lenvervimab,HBV (HBsAg),Prevention of Hepatitis B virus infection recurrence after liver transplantation,Terminated,Phase 2/3
Andecaliximab,MMP9,"Fibrodysplasia ossificans progressiva, Gastric Adenocarcinoma, Rheumatoid arthritis, chronic obstructive pulmonary disorders, ulcerative colitis, Solid tumors",Clinical,Phase 3
Otilimab ,GM-CSF,"COVID-19, Osteoarthritis, Rheumatoid Arthritis, Multiple Sclerosis",Terminated,Phase 3
Feladilimab,ICOS,"Head and neck cancer, Non-small cell lung cancer, advanced solid tumors, multiple myeloma (Phase 1/2 DREAMM5 study)",Terminated,Phase 3
Zalutumumab,EGFR,"Head and neck cancer, non-small cell lung cancer, colorectal cancer",Terminated,Phase 3
Omburtamab,B7-H3,Refractory Leptomeningeal Metastasis from Neuroblastoma (pediatric),Terminated,Regulatory review
"Lumiliximab, gomiliximab",CD23,"Asthma, chronic lymphocytic leukemia",Terminated,Phase 2/3
Epratuzumab,CD22,"Acute Lymphoblastic Leukaemia, Systemic Lupus Erythematosus, Waldenstrom Macroglobulinemia, Lymphoma ",Terminated,Phase 3
Clivatuzumab tetraxetan,MUC5AC,Pancreatic Cancer,Terminated,Phase 3
Fulranumab,NGF,"Pain associated with Osteoarthritis, Arthralgia, Joint Pain, Urologic Diseases, Diabetic Neuropathy, cancer-related pain in terminally ill patients, Neuralgia",Terminated,Phase 3
Talacotuzumab,CD123,"Acute Myeloid Leukemia, Myelodysplastic Syndromes",Terminated,Phase 2/3
Bermekimab,IL-1 alpha,"Systemic sclerosis, Atopic dermatitis, Hidradenitis Suppurativa, Colorectal cancer, Restenosis, Psoriasis, diabetes, Acne Vulgaris, cachexia in cancer patients, pyoderma gangrenosum, Neutrophilic Dermatoses ",Terminated,Regulatory review
Inolimomab,CD25,Graft-versus-host disease,Terminated,Phase 3
Roledumab,Rhesus D,"Hemolytic disease of newborns, idiopathic thrombocytopenic purpura",Terminated,Phase 2/3
Solanezumab,Amyloid beta (monomers),Alzheimer's Disease,Terminated,Terminated
Tabalumab,BAFF,"Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Myeloma, Multiple Sclerosis, Kidney Failure, Chronic",Terminated,Terminated
Bintrafusp alfa,"PD-L1, TGF beta","Soft-tissue Sarcoma, Triple Negative Breast Neoplasms, Nasopharyngeal Carcinoma, Uterine Cervical Neoplasms, non-small cell lung cancer, biliary tract cancer, solid tumors",Terminated,Terminated
Simaravibart,SARS-CoV-2 (spike protein),COVID-19,Terminated,Phase 2/3
Sabatolimab,TIM3,"Acute myeloid leukemia, Myelodysplastic syndrome, Advanced malignancies, acute myeloid leukemia or high risk myelodysplastic syndrome (single Phase 1 study)",Terminated,Phase 3
Motavizumab,RSV (F glycoprotein),Prevention of RSV infection in high risk infants,Terminated,Regulatory review
Tebotelimab,"LAG-3, PD-1","Melanoma, Head & neck cancer, Hepatocellular carcinoma, gastric cancer, Solid tumors",Terminated,Phase 2/3
Dalotuzumab,IGF-1R,"Breast Cancer, Colorectal Cancer, Non-small-cell Lung cancer, Neuroendocrine Tumors, Pancreatic Cancer, Solid Tumor, Multiple Myeloma",Terminated,Phase 2/3
"Actoxumab, bezlotoxumab",C. difficile (enterotoxin A and B),Clostridium difficile infection,Terminated,Phase 3
Gancotamab,HER2,Breast Cancer,Terminated,Phase 2/3
Farletuzumab,FR alpha,"Ovarian Cancer; Fallopian Tube Cancer, Peritoneal Neoplasms, Pituitary Adenoma, Lung Cancer",Terminated,Phase 3
Efungumab,HSP90,"Adjunctive therapy for Cryptococcal Meningitis in patients with AIDS, breast cancer",Terminated,Regulatory review
Ivuxolimab,OX40,"Kidney cancer, Advanced solid tumors",Terminated,Phase 3
Bococizumab,PCSK9,High cholesterol,Terminated,Phase 3
Utomilumab,4-1BB,"Colorectal cancer, breast cancer, diffuse Large B-Cell Lymphoma, Solid tumors, B cell malignancies",Terminated,Phase 3
Onartuzumab,cMET,"Non-Small Cell Lung Cancer, Glioblastoma, Gastric Cancer, Colorectal Cancer, Breast Cancer",Terminated,Phase 3
"Freneslerbart, mevonlerbart",Fel d 1,"Cat allergy, Allergy",Clinical,Phase 3
Suptavumab,RSV (F glycoprotein),"Phase 1 in healthy volunteers,  Prevention of Medically Attended RSV Infection in Preterm Infants",Terminated,Phase 3
Fasinumab,NGF,"Pain due to Osteoarthritis of the Knee or Hip Pain (Phase 3), low back pain (Phase 2/3)",Terminated,Phase 3
Lampalizumab,Factor D,Geographic atrophy associated with dry age-related macular degeneration,Terminated,Phase 3
Etrolizumab,Integrin beta-7,"Crohn's disease, Ulcerative Colitis",Terminated,Phase 3
Tanezumab,NGF,"Pain (osteoarthritis, post-surgical, chronic)",Terminated,Regulatory review
Gantenerumab,Amyloid beta (N-terminal and central portion aggregated and oligomers),Alzheimer's Disease,Terminated,Phase 3
Begelomab,CD26,Graft-versus-host disease,Terminated,Regulatory review
Tusamitamab ravtansine,CEA,"Gastric cancer, non-squamous Non-small-cell Lung Cancer , Non-small cell lung cancer, solid tumors",Terminated,Phase 3
Rovalpituzumab tesirine,DLL3,Small cell lung cancer,Terminated,Phase 3
Upanovimab,SARS-CoV-2 (spike protein),COVID-19,Terminated,Phase 2/3
Vadastuximab talirine,CD33,"Acute myeloid leukemia, Myelodysplastic Syndrome",Terminated,Phase 3
"Futuximab, modotuximab",EGFR,"Glioma, Lung cancer, Head and Neck cancers, Colorectal Cancer",Terminated,Phase 3
"Dafsolimab setaritox, grisnilimab setaritox","CD3, CD7",Graft vs host disease,Terminated,Phase 3
Otelixizumab,CD3,"Type 1 diabetes, psoriasis, Rheumatoid arthritis, transplant rejection",Terminated,Phase 3
Zilovertamab,ROR1,"Urothelial Carcinoma, Diffuse large B cell lymphoma, Mantle cell lymphoma, Chronic Lymphocytic Leukemia",Terminated,Phase 3
Oportuzumab monatox,EpCAM,"Bladder cancer, head and neck cancer",Terminated,Regulatory review
"Upinitatug rilsodotin, Upifitamab rilsodotin",NaPi2b,"Ovarian cancer, Cancers Likely to Express NaPi2b",Terminated,Phase 3
"Cosfroviximab, larcaviximab, porgaviximab",Ebola virus glycoprotein,Ebola infection,Terminated,Phase 2/3
Abagovomab,MUC16 idiotype,Ovarian cancer,Terminated,Phase 2/3
Belantamab mafodotin,BCMA,Multiple myeloma,Regulatory review,Regulatory review
Verenafusp alfa,Insulin receptor,Mucopolysaccharidosis Type II,Clinical,Phase 2/3
Vecantoxatug,Tetanus toxin,Tetanus prophylaxis,Clinical,Phase 3
